



12 November 2015, Melbourne, Australia: The Ophthalmology Innovation Summit (OIS) interviewed Opthea Limited's CEO & Managing Director Dr Megan Baldwin during the company's attendance at the OIS meeting in Las Vegas on Thursday 12 November 2015.

The interview can be viewed by clicking on the link:
<http://ois.net/opthea-taking-new-approach-to-combat-wet-amd/>

The OIS was attended by over 800 professionals from the investor, pharmaceutical and clinical ophthalmology community and was held in conjunction with the annual meeting of the American Association for Ophthalmology (AAO). AAO attracts more than 24,000 attendees annually and is the largest clinical ophthalmology conference in the US.

In addition to the interview, Dr Baldwin presented at the BioPharma Company Showcase of the OIS. The presentation covered the scientific rationale for targeting VEGF-C and VEGF-D for the treatment of wet AMD with Circadian's lead asset OPT-302, preclinical data and the design of the Phase 1/2A clinical trial that is currently actively recruiting patients at US clinical sites.

Dr Baldwin commented *"To be selected to present at this year's OIS is a great opportunity to showcase our OPT-302 program for wet AMD and build awareness of Circadian's technology to an international expert audience."*

A copy of the presentation is also available on Opthea's website ("News and Information", "Presentations") at www.opthea.com

Company & Media Enquiries:

Megan Baldwin, PhD
CEO & Managing Director
Opthea Limited
Tel: +61 (0) 3 9826 0399
Megan.baldwin@opthea.com

Rudi Michelson
Monsoon Communications
Tel: +61 (0) 3 9620 3333

Join our email database to receive program updates:

Tel: +61 (0) 3 9826 0399
info@opthea.com
www.opthea.com

About Opthea Limited

Opthea (ASX:OPT; OTCQX:CKDXY) is a biologics drug developer focusing on ophthalmic disease therapies. It controls exclusive worldwide rights to a significant intellectual property portfolio around Vascular Endothelial Growth Factor (VEGF)-C, VEGF-D and VEGFR-3. The applications for the VEGF technology, which functions in regulating blood and lymphatic vessel growth, are substantial and broad. Opthea's internal product development programs are primarily focused on developing OPT-302 (formerly VGX-300, soluble VEGFR-3) for 'back of the eye' disease such as wet age-related macular degeneration (wet AMD).